• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

    2/2/24 4:00:54 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GMDA alert in real time by email
    SC 13G/A 1 p24-0469sc13ga.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 3)*
     

    Gamida Cell Ltd.

    (Name of Issuer)
     

    Ordinary shares, par value NIS 0.01 per share

    (Title of Class of Securities)
     

    M47364100

    (CUSIP Number)
     

    December 31, 2023

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G/A is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 6 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. M47364100

    13G/A

    Page 2 of 6 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Highbridge Capital Management, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,222,973 Ordinary Shares issuable upon exchange of exchangeable notes

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,222,973 Ordinary Shares issuable upon exchange of exchangeable notes

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,222,973 Ordinary Shares issuable upon exchange of exchangeable notes

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.1%

    12

    TYPE OF REPORTING PERSON

    IA, OO

             

     

    CUSIP No. M47364100

    13G/A

    Page 3 of 6 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Gamida Cell Ltd. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 116 Huntington Avenue, 7th Floor, Boston, MA 02116.

     

    Item 2(a). NAME OF PERSON FILING:

     

     

    This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the Ordinary Shares (as defined in Item 2(d) below) issuable upon exchange of certain exchangeable notes directly held by the Highbridge Funds.

     

      The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.

     

    Item 2(c). CITIZENSHIP:

     

      Highbridge is a Delaware limited liability company.  

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Ordinary shares, par value NIS 0.01 per share (the "Ordinary Shares").

     

    Item 2(e). CUSIP NUMBER:
       
      M47364100

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,

     

     

    CUSIP No. M47364100

    13G/A

    Page 4 of 6 Pages

     

      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E),
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:________________________________

     

    Item 4. OWNERSHIP:
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page of the Reporting Person and is incorporated herein by reference.

     

    The percentages used herein are calculated based upon 132,638,514 Ordinary Shares outstanding as of November 10, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 14, 2023, and assumes the exchange of the exchangeable notes reported herein.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

     

    CUSIP No. M47364100

    13G/A

    Page 5 of 6 Pages

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      The Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. M47364100

    13G/A

    Page 6 of 6 Pages

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATED: February 2, 2024

     

    HIGHBRIDGE CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kirk Rule  
    Name: Kirk Rule  
    Title: Executive Director  
         

     

    Get the next $GMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMDA

    DatePrice TargetRatingAnalyst
    11/16/2021$14.00 → $12.00Buy
    Needham
    11/16/2021$17.00 → $15.00Outperform
    Oppenheimer
    11/1/2021$11.00Buy
    Alliance Global Partners
    More analyst ratings

    $GMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

      Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential of HB-200Sean Cassidy appointed to the Board of Directors NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice Pr

      7/22/24 8:30:00 AM ET
      $ARVN
      $GMDA
      $HOOK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • XORTX Welcomes New Member to the Board of Directors

      CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ))), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, welcomes Abigail Jenkins, a biotech industry veteran with deep experience with the commercialization of therapies for renal and cardiovascular disease, to its Board of Directors. Abigail "Abbey" L. Jenkins, M.S., is the current President and CEO of Gamida Cell (NASDAQ:GMDA) and a member of its Board of Directors. Ms. Jenkins brings over 20 years of leadership experience in the biopharmaceutical industry deliv

      4/8/24 7:30:00 AM ET
      $GMDA
      $XRTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $GMDA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:25 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:20 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Gamida Cell Ltd.

      EFFECT - Gamida Cell Ltd. (0001600847) (Filer)

      5/14/24 12:15:14 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Moch Kenneth I was granted 200,000 units of Ordinary Shares, increasing direct ownership by 619% to 232,300 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:55:12 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wills Stephen T was granted 200,000 units of Ordinary Shares, increasing direct ownership by 356% to 256,177 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:48:32 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tomasello Shawn was granted 200,000 units of Ordinary Shares, increasing direct ownership by 476% to 241,977 units (SEC Form 4)

      4 - Gamida Cell Ltd. (0001600847) (Issuer)

      2/2/24 4:45:46 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Gamida Cell with a new price target

      Needham reiterated coverage of Gamida Cell with a rating of Buy and set a new price target of $12.00 from $14.00 previously

      11/16/21 9:17:28 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer reiterated coverage on Gamida Cell with a new price target

      Oppenheimer reiterated coverage of Gamida Cell with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      11/16/21 8:13:09 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Gamida Cell with a new price target

      Alliance Global Partners initiated coverage of Gamida Cell with a rating of Buy and set a new price target of $11.00

      11/1/21 9:03:50 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      4/1/24 5:49:42 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:14:47 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Gamida Cell Ltd. (Amendment)

      SC 13G/A - Gamida Cell Ltd. (0001600847) (Subject)

      2/14/24 2:08:53 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

      For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

      4/17/23 1:02:15 PM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GMDA
    Financials

    Live finance-specific insights

    See more
    • Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results

      BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the fourth quarter and full year ended December 31, 2023 and provide an update on the company on Wednesday, March 27, 2024. Following the release, management will host a conference call and live webcast at 8:30 AM Eastern Time to discuss the financial results and provide a business update. Conference Call Dial-In & Webcast Information: Date/Time:Wednesday, March 27, 2024 at 8:30 AM Eastern TimeDomestic:1-877-425-9470International:1-201-389-0878Conference ID:13744446Call

      3/22/24 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Third Quarter 2023 Financial Results

      BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and answer questions. Conference Call Dial-In & Webcast Information:  Date/Time:Tuesday, November 14, 2023 at 8:30 AM Eastern Time Domestic:1-877-425-9470 International:1-201-389-0878 Conference ID:13741

      11/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gamida Cell to Report Second Quarter 2023 Financial Results

      Conference Call and Webcast Scheduled for Monday, August 14th at 8:30 am Eastern Time Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the second quarter ended June 30, 2023 on Monday, August 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corporate updates and answer questions. To access the conference call by phone, please register here and be advised to do so at least 10 minutes prior to joining. A live webcast of the conference call can be accessed b

      8/1/23 8:00:00 AM ET
      $GMDA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care